Good evening :)
Switch to
Place Order

Lupin Ltd

LUPIN
Health CarePharmaceuticals
LargecapWith a market cap of ₹50,271 cr, stock is ranked 90
Moderate RiskStock is 2.09x as volatile as Nifty
1,124.2516.85 (+1.52%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
LargecapWith a market cap of ₹50,271 cr, stock is ranked 90
Moderate RiskStock is 2.09x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
41.32
PB RatioPB Ratio
3.63
Dividend YieldDiv. Yield
0.59%
Sector PESector PE
39.89
Sector PBSector PB
5.75
Sector Div YldSctr Div Yld
0.62%

Forecast & RatingsDetailed Forecast 

51%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Lupin Limited is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.

Investor PresentationView older 

May 13, 2021

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

201820192020202115.9515.1015.9915.300.250.61-0.271.22
Revenue
Profit
Loss
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Decreased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has decreased by 1.63%

See detailed holdings

Recent EventsAll events 

Analysts/Institutional Investor Meet/Con. Call Updates 
Announced OnJul 31, 2021

Lupin Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates | Download

Lupin Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates | Download

Press Release 
Announced OnJul 30, 2021

Lupin Limited has informed the Exchange regarding a press release dated July 30, 2021, titled "Lupin Acquires Southern Cross Pharma in Australia.". | Download

Lupin Limited has informed the Exchange regarding a press release dated July 30, 2021, titled "Lupin Acquires Southern Cross Pharma in Australia.". | Download

Cash Dividend 
Ex. DateJul 27, 2021

Final • Div/Share: ₹ 6.5

See all events